Background Understanding and measuring the individual level of immune protection and its
persistence at both humoral and cellular levels after SARS-CoV-2 vaccination is mandatory …

The use of coronavirus disease 2019 (COVID-19) vaccines will play the major role in
helping to end the pandemic that has killed millions worldwide. COVID-19 vaccines have …

Since COVID-19 risk of reinfection is of great concern, the safety and efficacy of the mRNA-
based vaccines in previously infected populations should be assessed. We studied 78 …

Background The mRNA-based vaccine BNT162b2 of BioNTech/Pfizer has shown high
efficacy against SARS-CoV-2 infection and a severe course of the COVID-19 disease …

Public health vaccination recommendations for COVID-19 primary series and boosters in
previously infected individuals differ worldwide. As infection with SARS-CoV-2 is often …

Background SARS-CoV-2 vaccines are an invaluable resource against COVID-19. Current
vaccine shortage makes it necessary to prioritize distribution to the most appropriate …

Clinical trials and real-world evidence on COVID-19 vaccines have shown their
effectiveness against severe disease and death but the durability of protection remains …

The aim of our study was to investigate the immunogenicity of the BNT162b2 vaccination
according to the age and medical status of vaccinated individuals. A total of 511 individuals …

The standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two doses
administered three weeks apart. However, some public health authorities spaced these …

Background To optimise the use of available SARS-CoV-2 vaccines, some advocate
delaying second vaccination for individuals infected within six months. We studied whether …